Background: Chronic kidney disease (CKD) impairs intestinal barrier function which by allowing influx of noxious products causes systemic inflammation. We have recently shown that intestinal barrier dysfunction in CKD is due to degradation of epithelial tight junction (TJ) which is, in part, mediated by influx of urea and its conversion to ammonia by microbial urease. We hypothesized that by adsorbing urea and urea-derived ammonia, oral activated charcoal (AST-120) may ameliorate CKD-induced intestinal epithelial barrier disruption and systemic inflammation. Methods: Rats were randomized to the CKD or control groups. The CKD group was fed a chow containing 0.7% adenine for 2 weeks. They were then randomized to receive a chow with or without AST-120 (4 g/kg/day) for 2 weeks. Rats consuming regular diet served as controls. Animals were then euthanized, colons were removed and processed for Western blot and immunohistology, and plasma was used to measure endotoxin and oxidative and inflammatory markers. Results: Compared with the controls, the untreated CKD rats showed elevated plasma endotoxin, IL-6, TNF-α, MCP-1, CINC-3, L-selectin, ICAM-1, and malondialdehyde, and depletions of colonic epithelial TJ proteins, claudin-1, occludin, and ZO1. Administration of AST-120 resulted in partial restoration of the epithelial TJ proteins and reduction in plasma endotoxin and markers of oxidative stress and inflammation. Conclusions: CKD animals exhibited depletion of the key protein constituents of the colonic epithelial TJ which was associated with systemic inflammation, oxidative stress and endotoxemia. Administration of AST-120 attenuated uremia-induced disruption of colonic epithelial TJ and the associated endotoxemia, oxidative stress and inflammation.

1.
Turner JR: Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009;9:799-809.
2.
Nusrat A, Turner JR, Madara JL: Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am J Physiol Gastrointest Liver Physiol 2000;279:G851-G857.
3.
Cachofeiro V, Goicochea M, de Vinuesa SG, Oubiña P, Lahera V, Luño J: Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 2008;111:S4-S9.
4.
Stenvinkel P: Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton) 2006;11:36-41.
5.
Ruiz S, Pergola PE, Zager RA, Vaziri ND: Targeting Nrf2 activation to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int, DOI: 10.1038/ki.2012.439.
6.
Vaziri ND: CKD impairs barrier function and alters microbial flora of the intestine - a major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypertens 2012;21:587-592.
7.
Magnusson M, Magnusson KE, Sundqvist T, et al: Increased intestinal permeability to differently sized polyethylene glycols in uremic rats: effects of low- and high protein diets. Nephron 1990;56:306-311.
8.
Magnusson M, Magnusson KE, Sundqvist T, et al: Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut 1991;32:754-759.
9.
de Almeida Duarte JB, de Aguilar-Nascimento JE, Nascimento M, et al: Bacterial translocation in experimental uremia. Urol Res 2004;32:266-270.
10.
Vaziri ND, Dure-Smith B, Miller R, et al: Pathology of gastrointestinal tract in chronic hemodialysis patients: an autopsy study of 78 cases. Am J Gastroenterol 1985;80:608-611.
11.
Feroze U, Kalantar-Zadeh K, Sterling KA, Molnar MZ, Noori N, Benner D, Shah V, Dwivedi R, Becker K, Kovesdy CP, Raj DS: Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. J Ren Nutr 2012;22:317-326.
12.
Gonçalves S, Pecoits-Filho R, Perreto S, et al: Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. Nephrol Dial Transplant 2006;21:2788-2794.
13.
Szeto CC, Kwan BC, Chow KM, et al: Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol 2008;3:431-436.
14.
Vaziri ND, Yuan J, Rahimi A, Ni Z, Said H, Subramanian VS: Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. Nephrol Dial Transplant 2012;27:2686-2693.
15.
Vaziri ND, Goshtasby N, Yuan J, Jellbauer S, Moradi H, Raffatellu M, Kalantar-Zadeh K: Uremic human plasma degrades intestinal epithelial barrier structure and function. Am J Nephrol 2012;36:438-443.
16.
Vaziri ND, Yuan J, Norris K: Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am J Nephrol 2013;37:1-6.
17.
Goto S, Yoshiya K, Kita T, Fujii H, Fukagawa M: Uremic toxins and oral adsorbents. Ther Apher Dial 2011;15:132-134.
18.
Kikuchi K, Itoh Y, Tateoka R, Ezawa A, Murakami K, Niwa T: Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:2997-3002.
19.
Meyer TW, Hostetter TH: Uremic solutes from colon microbes. Kidney Int 2012;81:949-954.
20.
Aronov PA, Luo FJ, Plummer NS, Quan Z, Holmes S, Hostetter TH, Meyer TW: Colonic contribution to uremic solutes. J Am Soc Nephrol 2011;22:1769-1776.
21.
Niwa T: Recent progress in the analysis of uremic toxins by mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:2600-2606.
22.
Bolati D, Shimizu H, Niwa T: AST-120 ameliorates epithelial-to-mesenchymal transition and interstitial fibrosis in the kidneys of chronic kidney disease rats. J Ren Nutr 2012;22:176-180.
23.
Shibahara H, Shibahara N: Cardiorenal protective effect of the oral uremic toxin absorbent AST-120 in chronic heart disease patients with moderate CKD. J Nephrol 2010;23:535-540.
24.
Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Suzuki T, Ueda Y, Yamagishi S: Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation. Metabolism 2011;60:260-264.
25.
Ito S, Higuchi Y, Yagi Y, Nishijima F, Yamato H, Ishii H, Osaka M, Yoshida M: Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease. J Leukoc Biol 2013, Epub ahead of print.
26.
Niwa T: Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. Ther Apher Dial 2011;15:120-124.
27.
Vaziri ND, Ni Z, Oveisi F, et al: Effect of antioxidant therapy on blood pressure and NO synthase expression in hypertensive rats. Hypertension 2000;36:957-964.
28.
Yokozawa T, Zheng PD, Oura H and Koizumi F: Animal model of adenine-induced chronic renal failure in rats. Nephron 1986;44:230-234.
29.
Vaziri ND, Wong J, Pahl MV, Piceno YM, Yuan J, De Santis TZ, Ni Z, Nguyen TH, Andersen GL: Chronic kidney disease alters the composition of intestinal microbial flora. Kidney Int 2013;83:308-315.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.